Osiris Therapeutics Announces Positive One Year Data From Chondrogen Trial For Knee Repair

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced positive one-year interim results in the evaluation of Chondrogen, a preparation of adult stem cells formulated for direct injection into the knee. The one year data showed improvement in joint condition that correlated with a clinically and statistically significant improvement in pain in patients with osteoarthritis (OA) who received Chondrogen as compared to those treated with the control, hyaluronic acid (HA). [click link for full article]

More: continued here

Filed under: Arthritis on December 2nd, 2007